Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers
- PMID: 28360017
- DOI: 10.1016/j.molimm.2017.03.017
Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers
Abstract
Folate receptor alpha (FRα) is aberrantly expressed in ovarian cancers but largely absent in normal tissues, and therefore represents an attractive target for immunotherapy. In recent years, modification of T cells with chimeric antigen receptor (CAR) targeting FRα has been reported to improve antitumor immunity of T cells. However, there are limited data regarding CAR-modified cytokine-induced killer (CAR-CIK) cells. In the present study, we modified CIK cells with FRα-specific CARs and investigated their antitumor immunity against ovarian cancers. We found that both non-transduced and mock CAR-transduced CIK cells showed only low antitumor activity against either FRα-positive (FRα+) or FRα-negative (FRα-) targets. However, all three generations of CAR-modified CIK cells showed enhanced antitumor activity against FRα+ targets, but not FRα- targets. First-generation ζ-CAR-CIK cells increased production of IFN-γ, enhanced short-term cytotoxicity against FRα+ ovarian cancer cells, and showed modest and short-term suppression of established tumors; while second-generation 28ζ- and third-generation 28BBζ-CAR-CIK cells showed significant proliferation, enhanced secretion of IL-2, eliminated the FRα+ ovarian cancer cells in long-term co-culture, and showed dramatic and long-term inhibition of tumor growth and prolonged survival of xenograft-bearing mice. It is noteworthy that the 28BBζ-CAR was more potent in the modification of CIK cells than 28ζ-CAR both in vitro and in vivo. Moreover, CAR-CIK cells showed more efficient anticancer activity compared with CAR-T cells in vitro, but less efficient than CAR-T cells in vivo. According to these results, we conclude that modification of CIK cells with FRα-specific CARs enhances their antitumor immunity to FRα+ ovarian cancers. The third-generation 28BB-ζ CAR containing 4-1BB co-stimulation was more efficient in modification of CIK cells than either first-generation ζ-CAR or second-generation CD28-ζ-CAR.
Keywords: Chimeric antigen receptor; Cytokine induced killer cells; Folate receptor-alpha; Immunotherapy; Ovarian cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11. Int J Cancer. 2016. PMID: 27253354
-
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5. Cancer Res. 2011. PMID: 21546571 Free PMC article.
-
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".Mol Ther. 2013 Dec;21(12):2268-77. doi: 10.1038/mt.2013.192. Epub 2013 Aug 28. Mol Ther. 2013. PMID: 23985696 Free PMC article.
-
The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.Hum Immunol. 2015 May;76(5):385-91. doi: 10.1016/j.humimm.2014.09.021. Epub 2014 Oct 8. Hum Immunol. 2015. PMID: 25305457 Review.
-
How can Cytokine-induced killer cells overcome CAR-T cell limits.Front Immunol. 2023 Aug 22;14:1229540. doi: 10.3389/fimmu.2023.1229540. eCollection 2023. Front Immunol. 2023. PMID: 37675107 Free PMC article. Review.
Cited by
-
The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.World J Surg Oncol. 2025 Apr 22;23(1):153. doi: 10.1186/s12957-025-03745-x. World J Surg Oncol. 2025. PMID: 40264184 Free PMC article. Review.
-
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.Clin Cancer Res. 2020 Dec 1;26(23):6321-6334. doi: 10.1158/1078-0432.CCR-20-0357. Epub 2020 Sep 8. Clin Cancer Res. 2020. PMID: 32900797 Free PMC article.
-
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy.Cancers (Basel). 2023 Feb 7;15(4):1052. doi: 10.3390/cancers15041052. Cancers (Basel). 2023. PMID: 36831396 Free PMC article. Review.
-
From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.J Inflamm Res. 2022 Jul 17;15:4061-4085. doi: 10.2147/JIR.S368138. eCollection 2022. J Inflamm Res. 2022. PMID: 35873388 Free PMC article. Review.
-
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.Biomolecules. 2023 Mar 2;13(3):465. doi: 10.3390/biom13030465. Biomolecules. 2023. PMID: 36979400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials